Concord Wealth Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Concord Wealth Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-279	Closed	-$22K	–	1249
2022 Q1	$22K	Buy	279 +68	+32%	+$5.69K	0.01%	610
2021 Q4	$19K	Buy	211 +160	+314%	+$13.2K	﹤0.01%	653
2021 Q3	$4K	Buy	51 +42	+467%	+$3.31K	﹤0.01%	616
2021 Q2	$1K	Hold	9	–	–	﹤0.01%	949
2021 Q1	$1K	Buy	+9	New	+$735	﹤0.01%	887

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Concord Wealth Partners's BMRN Position: Q2 2022 in Review

Concord Wealth Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 279 shares — an estimated $22K sold.

Concord Wealth Partners first reported a position in BMRN in Q1 2021 and held it in 5 quarters. The position peaked at $22K in Q1 2022. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Concord Wealth Partners reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Concord Wealth Partners sold 279 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $22K.
Concord Wealth Partners first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Concord Wealth Partners's BioMarin Pharmaceuticals position peaked at $22K in Q1 2022.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Concord Wealth Partners's 13F filing for Q2 2022, filed 4 Aug 2022.